Efficacy of neoadjuvant therapy and surgical rescue for locally advanced hepatoblastomas: 10 year single-center experience and literature review

Table 1 Patients features and outcomes

Age (yr)	PRE-TEXT pre-QT	Segments involved at diagnosis	AFP at diagnosis (ng/mL)	Histology	Chemotherapy(No. of cycles)	POST-TEXT at surgery (localization)	Surgery	Postoperative events	Follow-up (mo)	Current status
3	III, P1 (right branch)	I, V, VI, VII, VIII	18597.37	Embryonal	Neoadjuvant PLA (4 cycles) + adjuvant (2c)	II (V, VI, VII, VIII)	Right hepatectomy	Subphrenic abscess (drainage)	18	CR
4	II, P1 (left branch)	IVb, V, VIII	551.21	Epithelial mesenchymal mixed	Neoadjuvant PLA (4c) + adjuvant (2c)	I (IVb)	Segmentectomy IVb	Uneventful	19	CR
8	I	II, III	473856.00	Epithelial fetal	Neoadjuvant PLADO (4c) + adjuv (2c)	I (II, III)	Left hepatectomy	Uneventful	56	CR
13	I	VIII	14277.00	Epithelial fetal	Neoadjuvant PLA (4c) + adjuv (2c)	I (VIII)	Right hepatectomy	Uneventful	28	CR
15	I	VI	401800.00	Epithelial mesenchymal mixed	Adjuvant PLADO (4c)	I (VI)	Tumorectomy	Uneventful	106	CR
25	II, P1 (right branch)	V, VI, VII, VIII	83100.50	Embryonal fetal epithelial	Neoadjuvant PLADO (4c) + adjuv (2c)	II, P0 (VII, VIII)	Bisegmentectomy VII, VIII	Uneventful	13	Lung metastasis
31	I	VI	379.00	Epithelial	Adjuvant PLADO (4c)	I (VI)	Segmentectomy VI	Uneventful	50	CR

PLA: Cisplatin; DO: Doxorubicin; P1: Involvement of either the left or the right branch of the portal vein; CR: Complete remission.